<?xml version="1.0" encoding="UTF-8"?>
<p>As access to HAART is rolled out globally, WHO Global HIV Resistance Network recommends periodic monitoring of TDR (among acutely and recently infected drug-naïve persons [mean seroconversion period: 180 days [
 <xref rid="pone.0171124.ref013" ref-type="bibr">13</xref>,
 <xref rid="pone.0171124.ref018" ref-type="bibr">18</xref>]]) in RLS [
 <xref rid="pone.0171124.ref019" ref-type="bibr">19</xref>,
 <xref rid="pone.0171124.ref020" ref-type="bibr">20</xref>] where there is limited availability and treatment options of ARVs, hence ensuring effective treatment [
 <xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,
 <xref rid="pone.0171124.ref021" ref-type="bibr">21</xref>,
 <xref rid="pone.0171124.ref022" ref-type="bibr">22</xref>]. TDR has a potential to compromise treatment [
 <xref rid="pone.0171124.ref017" ref-type="bibr">17</xref>,
 <xref rid="pone.0171124.ref022" ref-type="bibr">22</xref>–
 <xref rid="pone.0171124.ref024" ref-type="bibr">24</xref>] despite apposite prescribing and adherence [
 <xref rid="pone.0171124.ref015" ref-type="bibr">15</xref>]. In resource-rich settings (RRS), moderate levels of TDR have been observed [
 <xref rid="pone.0171124.ref004" ref-type="bibr">4</xref>] but are either stabilizing or declining due to universal availability of highly efficacious drugs [
 <xref rid="pone.0171124.ref025" ref-type="bibr">25</xref>]. Many regions in sSA have low to moderate TDR levels, but urban sites have begun to show an increase [
 <xref rid="pone.0171124.ref006" ref-type="bibr">6</xref>,
 <xref rid="pone.0171124.ref010" ref-type="bibr">10</xref>,
 <xref rid="pone.0171124.ref011" ref-type="bibr">11</xref>,
 <xref rid="pone.0171124.ref016" ref-type="bibr">16</xref>,
 <xref rid="pone.0171124.ref026" ref-type="bibr">26</xref>–
 <xref rid="pone.0171124.ref033" ref-type="bibr">33</xref>]. Data on TDR in RLS are scarce, with drug resistance testing not routinely performed [
 <xref rid="pone.0171124.ref021" ref-type="bibr">21</xref>].
</p>
